



## Clinical trial results:

### An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome.

#### Summary

EudraCT number	2013-002562-39
Trial protocol	NL
Global end of trial date	04 January 2016

#### Results information

Result version number	v1 (current)
This version publication date	27 April 2017
First version publication date	27 April 2017

#### Trial information

##### Trial identification

Sponsor protocol code	CL2-78989-018
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Institut de Recherches Internationales Servier
Sponsor organisation address	50 rue Carnot, Suresnes, France,
Public contact	ITP (Innovative Therapeutic Pole), Institut de Recherches Internationales Servier, +33 15572 4366, clinicaltrials@servier.com
Scientific contact	ITP (Innovative Therapeutic Pole), Institut de Recherches Internationales Servier, +33 15572 4366, clinicaltrials@servier.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 January 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 January 2016
Global end of trial reached?	Yes
Global end of trial date	04 January 2016
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The objective of this study is to explore the efficacy and safety of gevokizumab in patients with Schnitzler syndrome.

Protection of trial subjects:

This study was conducted in accordance with Good Clinical Practice standards, ethical principles stated in the Declaration of Helsinki and applicable regulatory requirements. After the subject has ended his/her participation in the trial, the investigator provided appropriate medication and/or arranged access to appropriate care for the patient.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 December 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 3
Worldwide total number of subjects	3
EEA total number of subjects	3

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	3
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Males or females aged  $\geq 18$  years with diagnosis of Schnitzler syndrome at least one year prior, and with active Schnitzler syndrome disease as defined by the presence of at least 2 of 3 clinical criteria (from rash, fever (defined as  $\geq 38^{\circ}\text{C}$ ) and bone or arthritis pain) and elevated CRP levels  $\geq 30$  mg/L, and without clinical signs of tuberculosis.

### Period 1

Period 1 title	Treatment period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Gevokizumab
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Gevokizumab
Investigational medicinal product code	S78989
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Gevokizumab was administered to 3 patients with starting dose of 60 mg and were to receive maximum dose of 180 mg per 2-week period over a 2-year treatment duration.

<b>Number of subjects in period 1</b>	Gevokizumab
Started	3
Completed	3

## Baseline characteristics

---

### Reporting groups

---

Reporting group title	Treatment period
-----------------------	------------------

---

Reporting group description: -

<b>Reporting group values</b>	Treatment period	Total	
Number of subjects	3	3	
Age categorical Units: Subjects			
From 65-84 years	3	3	
Gender categorical Units: Subjects			
Female	2	2	
Male	1	1	

## End points

---

### End points reporting groups

Reporting group title	Gevokizumab
-----------------------	-------------

Reporting group description: -

---

### Primary: no primary criterion

End point title	no primary criterion <sup>[1]</sup>
-----------------	-------------------------------------

End point description:

End point type	Primary
----------------	---------

End point timeframe:

As the study was exploratory, no primary endpoint was defined.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As no primary endpoint was defined for this exploratory study, no statistical analysis was performed.

End point values	Gevokizumab			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[2]</sup>			
Units: no unit				

Notes:

[2] - As the study was exploratory, no primary endpoint was defined.

---

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All adverse events which occurred during the treatment period are presented here.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.0
--------------------	------

### Reporting groups

Reporting group title	Gevokizumab
-----------------------	-------------

Reporting group description: -

<b>Serious adverse events</b>	Gevokizumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 3 (33.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Gevokizumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)		
Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Fall			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Head injury			

<p>subjects affected / exposed occurrences (all)</p> <p>Vaccination complication subjects affected / exposed occurrences (all)</p>	<p>1 / 3 (33.33%) 1</p> <p>1 / 3 (33.33%) 1</p>		
<p>Nervous system disorders Somnolence subjects affected / exposed occurrences (all)</p>	<p>1 / 3 (33.33%) 1</p>		
<p>General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)</p> <p>Feeling cold subjects affected / exposed occurrences (all)</p> <p>General physical health deterioration subjects affected / exposed occurrences (all)</p> <p>Malaise subjects affected / exposed occurrences (all)</p>	<p>1 / 3 (33.33%) 2</p> <p>1 / 3 (33.33%) 1</p> <p>1 / 3 (33.33%) 1</p> <p>1 / 3 (33.33%) 1</p>		
<p>Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)</p> <p>Abdominal pain upper subjects affected / exposed occurrences (all)</p> <p>Diarrhoea subjects affected / exposed occurrences (all)</p> <p>Dry mouth subjects affected / exposed occurrences (all)</p> <p>Dyspepsia</p>	<p>1 / 3 (33.33%) 1</p> <p>1 / 3 (33.33%) 1</p> <p>2 / 3 (66.67%) 3</p> <p>1 / 3 (33.33%) 1</p>		

<p>subjects affected / exposed occurrences (all)</p> <p>Eructation subjects affected / exposed occurrences (all)</p> <p>Nausea subjects affected / exposed occurrences (all)</p>	<p>1 / 3 (33.33%) 1</p> <p>1 / 3 (33.33%) 1</p> <p>1 / 3 (33.33%) 1</p>		
<p>Reproductive system and breast disorders Atrophic vulvovaginitis subjects affected / exposed occurrences (all)</p>	<p>1 / 3 (33.33%) 1</p>		
<p>Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)</p> <p>Epistaxis subjects affected / exposed occurrences (all)</p> <p>Nasal congestion subjects affected / exposed occurrences (all)</p> <p>Oropharyngeal pain subjects affected / exposed occurrences (all)</p>	<p>1 / 3 (33.33%) 2</p> <p>1 / 3 (33.33%) 1</p> <p>1 / 3 (33.33%) 3</p> <p>1 / 3 (33.33%) 1</p>		
<p>Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)</p> <p>Stress subjects affected / exposed occurrences (all)</p>	<p>1 / 3 (33.33%) 1</p> <p>1 / 3 (33.33%) 1</p>		
<p>Musculoskeletal and connective tissue disorders Arthralgia</p>			

subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	2		
Back pain			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Metatarsalgia			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Musculoskeletal stiffness			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Neck pain			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Osteoarthritis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Infections and infestations			
Bronchitis viral			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Cystitis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Gastrointestinal viral infection			
subjects affected / exposed	2 / 3 (66.67%)		
occurrences (all)	2		
Oral herpes			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	4		
Respiratory tract infection bacterial			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		

Sinusitis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Viral upper respiratory tract infection			
subjects affected / exposed	2 / 3 (66.67%)		
occurrences (all)	3		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 July 2014	At inclusion, the starting dose of gevokizumab was increased to 180 mg; as no patient was recruited after the amendment, all included patients received a starting dose of 60 mg as per initial protocol. For on-going patients, the maximum authorised dose was increased up to 180 mg gevokizumab per 2-week period if deemed appropriate by the investigator according to the patient's clinical response over the 2-year treatment period.
21 October 2014	The overall follow-up of patient was extended from 1 to 2 years.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported